Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Puma Biotechnology (PBYI) Shares Outstanding (Weighted Average) (2017 - 2025)

Puma Biotechnology (PBYI) has disclosed Shares Outstanding (Weighted Average) for 9 consecutive years, with $50.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) rose 2.8% year-over-year to $50.0 million, compared with a TTM value of $50.0 million through Dec 2025, up 2.8%, and an annual FY2025 reading of $50.0 million, up 2.8% over the prior year.
  • Shares Outstanding (Weighted Average) was $50.0 million for Q4 2025 at Puma Biotechnology, up from $48.6 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $50.0 million in Q4 2025 and bottomed at $40.6 million in Q4 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $46.2 million, with a median of $47.1 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Weighted Average) increased 2.69% in 2021, then increased 9.93% in 2022.
  • Year by year, Shares Outstanding (Weighted Average) stood at $40.6 million in 2021, then grew by 9.93% to $44.7 million in 2022, then increased by 5.51% to $47.1 million in 2023, then grew by 3.21% to $48.6 million in 2024, then rose by 2.8% to $50.0 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for PBYI at $50.0 million in Q4 2025, $48.6 million in Q4 2024, and $47.1 million in Q4 2023.